Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Cash from Investing Activities for 9 consecutive years, with -$713000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 18.05% year-over-year to -$713000.0; the TTM value through Mar 2026 reached -$2.5 million, down 34.59%, while the annual FY2025 figure was -$2.4 million, 90.28% down from the prior year.
  • Cash from Investing Activities hit -$713000.0 in Q1 2026 for Bicycle Therapeutics, down from -$574000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$12000.0 in Q1 2024 and bottomed at -$9.8 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$1.5 million, with a median of -$574000.0 recorded in 2025.
  • Year-over-year, Cash from Investing Activities tumbled 5630.41% in 2022 and then surged 99.43% in 2024.
  • Bicycle Therapeutics' Cash from Investing Activities stood at -$1.4 million in 2022, then soared by 96.48% to -$51000.0 in 2023, then plummeted by 621.57% to -$368000.0 in 2024, then tumbled by 55.98% to -$574000.0 in 2025, then fell by 24.22% to -$713000.0 in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$713000.0, -$574000.0, and -$674000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.